ProfessorRobert Glen
Chair in Computational Medicine
Department of Metabolism, Digestion and Reproduction - Faculty of Medicine
Orcid identifier0000-0003-1759-2914 (opens in a new tab)
- Chair in Computational MedicineDepartment of Metabolism, Digestion and Reproduction - Faculty of Medicine
- 020 7594 7912 (Work)
- Imperial College London, Metabolism Digestion and Reproduction, Burlington-Danes, Du Cane Rd, London, Hammersmith Campus, United Kingdom, W12 0TN, United Kingdom
BIO
I gained my Ph.D. (supervisor Prof. Peter Murray-Rust) in X-ray Crystallography, computational chemistry and Organic Synthesis from the University of Stirling. One of the highlights was the first co-crystallisation of a reactant and product of a chemical reaction in a single crystal.
As a Senior Research Scientist at the Wellcome Foundation I guided the development of the Computer-aided Molecular Design group. This included Protein Crystallography (the first in a pharmaceutical company), Molecular Transport properties and Electrochemistry. I designed the GASP and GOLD computer programs which are used extensively in the pharmaceutical industry, I am a co-inventor of Zomig (a drug for migraine) and invented two other compounds that have entered Phase-2 clinical development.
As Vice President for Collaborative Research at Tripos Inc., a biotechnology company in St. Louis Mo. we created the first commercial screening library, Optiverse (100K compounds), and I assisted in setting up three biotechnology companies (Arena Pharmaceuticals, Phase-1 Molecular Toxicology and Signase). I obtained and directed a significant BBSRC grant with University College London (discovering activators of soluble guanylate cyclise and working with The Technology Partnership to develop the Baseplate robot) and managed collaborative research and contract research in drug discovery with many large Pharmaceutical companies. Two of the research programs resulted in drugs for obesity and sleep disorders.
In 1999 I moved to the University of Cambridge as Founder and Director of the Unilever Centre for Molecular Sciences Informatics (over 700 publications), as part of the Chemistry department, now part of the Theoretical Group. In 2020 I retired form Cambridge and am now Emeritus Professor. Current research includes AI/Machine Learning in chemistry/cheminformatics and discovery of new drugs for cancer and cardiovascular disease.
I was elected Professor of Computational Medicine at Imperial College London in 2014 and direct several groups working on Big Data projects in diverse areas such as metabonomics, clinical data analysis, bioinformatics and machine learning. I am closely involved with the National Phenome Centre, the Institute of Translational Medicine and Therapeutics, MedBio/HDR-UK and the Institute of Cancer Research. Research themes include 'omics data fusion, visualisation of complex high dimensional data, clinical spectroscopic data analysis and chemistry in epidemiological studies.
Lectures
I regularly lecture at conferences, companies and to undergraduates and post graduates e.g. 2023 Gordon Conference in Computer Aided Drug Discovery (Plenary Lecture).
Grants and activities
I have served on the boards of a number of emerging biotech and technology companies and serve on a number of grant awarding bodies and am a Fellow of Clare College Cambridge and the Royal Society of Chemistry. I have been a consultant to many large pharma companies. I have additionally received over £20M in grants over the last ten years, from Wellcome Trust, NHS, EPSRC, CRUK, BBSRC, DTI, MRC and Pharmaceutical and software companies.
As a Senior Research Scientist at the Wellcome Foundation I guided the development of the Computer-aided Molecular Design group. This included Protein Crystallography (the first in a pharmaceutical company), Molecular Transport properties and Electrochemistry. I designed the GASP and GOLD computer programs which are used extensively in the pharmaceutical industry, I am a co-inventor of Zomig (a drug for migraine) and invented two other compounds that have entered Phase-2 clinical development.
As Vice President for Collaborative Research at Tripos Inc., a biotechnology company in St. Louis Mo. we created the first commercial screening library, Optiverse (100K compounds), and I assisted in setting up three biotechnology companies (Arena Pharmaceuticals, Phase-1 Molecular Toxicology and Signase). I obtained and directed a significant BBSRC grant with University College London (discovering activators of soluble guanylate cyclise and working with The Technology Partnership to develop the Baseplate robot) and managed collaborative research and contract research in drug discovery with many large Pharmaceutical companies. Two of the research programs resulted in drugs for obesity and sleep disorders.
In 1999 I moved to the University of Cambridge as Founder and Director of the Unilever Centre for Molecular Sciences Informatics (over 700 publications), as part of the Chemistry department, now part of the Theoretical Group. In 2020 I retired form Cambridge and am now Emeritus Professor. Current research includes AI/Machine Learning in chemistry/cheminformatics and discovery of new drugs for cancer and cardiovascular disease.
I was elected Professor of Computational Medicine at Imperial College London in 2014 and direct several groups working on Big Data projects in diverse areas such as metabonomics, clinical data analysis, bioinformatics and machine learning. I am closely involved with the National Phenome Centre, the Institute of Translational Medicine and Therapeutics, MedBio/HDR-UK and the Institute of Cancer Research. Research themes include 'omics data fusion, visualisation of complex high dimensional data, clinical spectroscopic data analysis and chemistry in epidemiological studies.
Lectures
I regularly lecture at conferences, companies and to undergraduates and post graduates e.g. 2023 Gordon Conference in Computer Aided Drug Discovery (Plenary Lecture).
Grants and activities
I have served on the boards of a number of emerging biotech and technology companies and serve on a number of grant awarding bodies and am a Fellow of Clare College Cambridge and the Royal Society of Chemistry. I have been a consultant to many large pharma companies. I have additionally received over £20M in grants over the last ten years, from Wellcome Trust, NHS, EPSRC, CRUK, BBSRC, DTI, MRC and Pharmaceutical and software companies.
ACADEMIC POSITIONS
- Professor of Computational MedicineImperial College of Science Technology and Medicine, Surgery and Cancer, London, United Kingdom1 Feb 2014 - present
- Professor of Molecular Sciences InformaticsUniversity of Cambridge, Chemistry, Cambridge, United Kingdom1 Jun 2009 - present
NON-ACADEMIC POSITIONS
- Senior ScientistWellcome Research Laboratories, Physical Chemistry, Beckenham, United Kingdom1 Oct 1981 - 1 Jun 1995
- Senior Vice PresidentTripos Inc., Saint Louis, United States1 Aug 1995 - 30 May 1999
DEGREES
- BScPaisley College of Technology, Paisley, United Kingdom1 Oct 1974 - 30 Jun 1978
- PhDUniversity of Stirling, Stirling, United Kingdom1 Oct 1978 - 30 Jun 1981
FACULTY
- Faculty of Medicine
POSITION NAME
- Chair in Computational Medicine